<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760342</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-PK20</org_study_id>
    <nct_id>NCT02760342</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin</brief_title>
  <official_title>ASP015K Pharmacokinetic Study: Evaluation of Drug-Drug Interaction Between ASP015K and Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the pharmacokinetic interactions between ASP015K&#xD;
      and metformin in healthy non-elderly male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2016</start_date>
  <completion_date type="Actual">June 26, 2016</completion_date>
  <primary_completion_date type="Actual">June 26, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) parameter of metformin in plasma: AUCinf</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of metformin in plasma: Cmax</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>Cmax: Maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of metformin in plasma: AUClast</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>AUClast: Area under the concentration-time curve from the time of dosing to the last measurable concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metformin in plasma: CL/F</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>CL/F: Apparent total systemic clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metformin in plasma: t1/2</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metformin in plasma: tmax</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>tmax: Time of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metformin in plasma: Vz/F</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>Vz/F: Apparent volume of distribution during the terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metformin in urine: Aelast</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>Aelast: Amount of metformin excreted into the urine from the time of dosing to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metformin in urine: Aelast%</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>Aelast%: Percent of metformin excreted into the urine from the time of dosing to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metformin in urine: CLR</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>CLR: Renal clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP015K in plasma: AUCinf</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP015K in plasma: AUClast</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP015K in plasma: AUCtau</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>AUCtau: Area under the concentration-time curve from the time of dosing to the start of the next dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP015K in plasma: CL/F</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP015K in plasma: Cmax</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP015K in plasma: Ctrough</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>Ctrough: Concentration immediately prior to dosing at multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP015K in plasma: PTR</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>PTR: Peak trough ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP015K in plasma: Rac</measure>
    <time_frame>Up to Day 12</time_frame>
    <description>Rac: accumulation ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP015K in plasma: t1/2</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP015K in plasma: tmax</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP015K in plasma: Vz/F</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metabolites of ASP015K in plasma: AUCinf</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metabolites of ASP015K in plasma: AUClast</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metabolites of ASP015K in plasma: AUCtau</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metabolites of ASP015K in plasma: Cmax</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metabolites of ASP015K in plasma: Ctrough</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metabolites of ASP015K in plasma: PTR</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metabolites of ASP015K in plasma: Rac</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metabolites of ASP015K in plasma: t1/2</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of metabolites of ASP015K in plasma: tmax</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Adverse events</measure>
    <time_frame>Up to 17 days after first study drug dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal vital signs and/or adverse events related to treatment</measure>
    <time_frame>Up to 17 days after first study drug dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal laboratory values and/or adverse events related to treatment</measure>
    <time_frame>Up to 17 days after first study drug dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal standard 12-lead ECG and/or adverse events related to treatment</measure>
    <time_frame>Up to 17 days after first study drug dosing</time_frame>
    <description>ECG: Electrocardiogram</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>ASP015K and Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single oral dose of metformin on Days 1 and 10, a single dose of ASP015K on Day 3 and multiple doses of ASP015K once daily Day 5 to Day 11. Subjects will receive a single dose of metformin and ASP015K concurrently on Day 10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peficitinib</intervention_name>
    <description>Oral</description>
    <arm_group_label>ASP015K and Metformin</arm_group_label>
    <other_name>ASP015K</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Oral</description>
    <arm_group_label>ASP015K and Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight at screening: ≥ 50.0 kg, &lt; 80.0 kg&#xD;
&#xD;
          -  BMI at screening: ≥ 17.6, &lt; 26.4&#xD;
&#xD;
          -  Subjects who agree to use highly effective contraception as consisting of two forms of&#xD;
             birth control (at least one of which must be a barrier method) from getting informed&#xD;
             consent through 90 days after the final study drug administration.&#xD;
&#xD;
          -  Subjects who agree NOT to donate sperm from getting informed consent through 90 days&#xD;
             after the final study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who received or are scheduled to receive any investigational drugs in other&#xD;
             clinical trials or post-marketing studies within 120 days before screening test or&#xD;
             during the screening test to the hospital admission (Day -1).&#xD;
&#xD;
          -  Subjects who received or is scheduled to receive any medications (including&#xD;
             over-the-counter drugs) within seven days before the hospital admission (Day -1).&#xD;
&#xD;
          -  Subjects who received ASP015K or metformin previously.&#xD;
&#xD;
          -  Subjects who have a habit of excessive alcohol drinking or smoking.&#xD;
&#xD;
          -  Any deviation from the normal range of blood pressure, pulse, body temperature, or&#xD;
             12-lead ECG at screening or on the day of hospital admission (Day -1).&#xD;
&#xD;
          -  Subjects who meet any of the following criterion for laboratory tests at screening or&#xD;
             on the day of hospital admission (Day -1). Normal ranges of each test specified at the&#xD;
             study site or test/assay organization will be used as the normal ranges in this study.&#xD;
&#xD;
          -  Subjects with a complication or history of drug allergies.&#xD;
&#xD;
          -  Subjects who have a history of clinically serious allergy, which induces generalized&#xD;
             urticaria or anaphylactic shock requiring hospital admission.&#xD;
&#xD;
          -  Subjects with a complication or history of hepatic disease, renal disease, cardiac&#xD;
             disease, congenital short QT syndrome, respiratory disease , gastrointestinal disease.&#xD;
&#xD;
          -  Subjects with a history of gastrointestinal resection.&#xD;
&#xD;
          -  Subjects who developed upper gastrointestinal symptoms within seven days before the&#xD;
             hospital admission (Day -1).&#xD;
&#xD;
          -  Subjects with a complication or history of endocrine disease, cerebrovascular disease,&#xD;
             malignant tumor, lymphatic disease , lactic acidosis.&#xD;
&#xD;
          -  Subjects who apply to any of the concerns with regard to tuberculosis.&#xD;
&#xD;
          -  Subjects who apply to any of the concerns with regard to infection other than&#xD;
             tuberculosis.&#xD;
&#xD;
          -  Subjects with vaccination of live vaccines or live attenuated vaccines within 56 days&#xD;
             before the hospital admission (Day -1).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 1, 2016</study_first_submitted>
  <study_first_submitted_qc>May 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Metformin</keyword>
  <keyword>Drug-drug interaction</keyword>
  <keyword>ASP015K</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Peficitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

